Daniel A. Laheru

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial

  Nature Communications · 2026-06-23

• Supplementary Table 2 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors

  2026-06-17

• Supplementary Table 3 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors

  2026-06-17

• Supplementary Table 1 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors

  2026-06-17

• Widespread Hyperalgesia Predicts Mortality in Pancreatic Adenocarcinoma

  medRxiv · 2026-05-27

• Abstract CT016: Feasibility and efficacy of perioperative nivolumab with or without relatlimab for patients with potentially resectable hepatocellular carcinoma

  Cancer Research · 2026-04-17

• Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial

  Nature Communications · 2026-04-15

• Abstract 6541: Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinoma

  Cancer Research · 2026-04-03

• The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study

  Nature Communications · 2026-03-18

• Supplementary Figure 6 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

  2025-12-15

• Supplementary Table 3 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

  2025-12-15

• Supplementary Table 7 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

  2025-12-15

• Supplementary Table 8 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

  2025-12-15

• Supplementary Table 4 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

  2025-12-15

• Supplementary Figure 5 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

  2025-12-15

• Supplementary Figure 2 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

  2025-12-15

• Supplementary Figure 1 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

  2025-12-15

• Supplementary Table 5 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

  2025-12-15

• Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

  Clinical Cancer Research · 2025-12-15

• 497 A mutant KRAS peptide vaccine (mKRAS-VAX) combined with immune checkpoint blockade recruits vaccine-induced T-cells into metastatic MMRp/MSS colorectal tumors

  Regular and Young Investigator Award Abstracts · 2025-11-01